Last reviewed · How we verify
Glucophage® Long
At a glance
| Generic name | Glucophage® Long |
|---|---|
| Also known as | fasting condition, fed condition |
| Sponsor | Geropharm |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India) (PHASE3)
- Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease (PHASE4)
- Randomized Sitagliptin Withdrawal Study (MK-0431-845) (PHASE3)
- Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005) (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) (PHASE3)
- A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016) (PHASE3)
- Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients (PHASE4)
- A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |